Trimeprazine Tartrate

CHEMBL3989885 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
747.0 g/mol
LogP
Phase
4

Trimeprazine tartrate is a phenothiazine derivative with potent antihistamine and sedative properties, acting as an H1 receptor antagonist with additional anticholinergic and antidopaminergic effects. It is used to relieve pruritus (itching) associated with allergic conditions and as a preoperative sedative, particularly in pediatric patients. The tartrate salt form enhances solubility for pharmaceutical formulation.

น้ำหนักโมเลกุล

747.0000 g/mol

TPSA

179.00 Ų

กลไกการออกฤทธิ์

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(CN(C)C)CN1c2ccccc2Sc2ccccc21.CC(CN(C)C)CN1c2ccccc2Sc2ccccc21.O=C(O)C(O)C(O)C(=O)O

InChI

InChI=1S/2C18H22N2S.C4H6O6/c2*1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20;5-1(3(7)8)2(6)4(9)10/h2*4-11,14H,12-13H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)

Molecular Formula

C40H50N4O6S2

HBD / HBA

4 / 12

พันธะที่หมุนได้

11

อะตอมหนัก

52

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Trimeprazine tartrate is a phenothiazine derivative with potent antihistamine and sedative properties, acting as an H1 receptor antagonist with additional anticholinergic and antidopaminergic effects. It is used to relieve pruritus (itching) associated with allergic conditions and as a preoperative sedative, particularly in pediatric patients. The tartrate salt form enhances solubility for pharmaceutical formulation.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Trimeprazine Tartrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989885. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 441236. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.